Hebei Changshan Biochem Pharma (300255) — Working Capital to Net Assets Ratio
Hebei Changshan Biochem Pharma (300255) has a Working Capital to Net Assets ratio of -20.8% as of September 2025. Working capital of CN¥-307.14 Million (current assets of CN¥2.08 Billion minus current liabilities of CN¥2.38 Billion) is measured against net assets of CN¥1.48 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 300255 equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hebei Changshan Biochem Pharma Working Capital to Net Assets (2008–2024)
This chart shows how Hebei Changshan Biochem Pharma's Working Capital to Net Assets ratio has evolved across 17 annual periods from 2008 to 2024. As of September 2025, the ratio stands at -20.8%, reflecting working capital of CN¥-307.14 Million against net assets of CN¥1.48 Billion CNY. Check Hebei Changshan Biochem Pharma tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Hebei Changshan Biochem Pharma (2008–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hebei Changshan Biochem Pharma from 2008 to 2024, covering 17 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 300255 market cap.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -13.0% | CN¥-200.38 Million | CN¥1.54 Billion | CN¥2.00 Billion | CN¥2.20 Billion | ▼ -32.8 pp |
| 2023 | 19.7% | CN¥354.94 Million | CN¥1.80 Billion | CN¥2.28 Billion | CN¥1.92 Billion | ▼ -49.4 pp |
| 2022 | 69.1% | CN¥2.11 Billion | CN¥3.05 Billion | CN¥3.90 Billion | CN¥1.79 Billion | ▲ +14.6 pp |
| 2021 | 54.5% | CN¥1.67 Billion | CN¥3.07 Billion | CN¥3.41 Billion | CN¥1.73 Billion | ▼ -1.1 pp |
| 2020 | 55.6% | CN¥1.59 Billion | CN¥2.85 Billion | CN¥3.00 Billion | CN¥1.41 Billion | ▲ +6.2 pp |
| 2019 | 49.4% | CN¥1.35 Billion | CN¥2.72 Billion | CN¥2.53 Billion | CN¥1.19 Billion | ▼ -10.7 pp |
| 2018 | 60.1% | CN¥1.52 Billion | CN¥2.52 Billion | CN¥2.60 Billion | CN¥1.09 Billion | ▼ -3.2 pp |
| 2017 | 63.3% | CN¥1.54 Billion | CN¥2.44 Billion | CN¥2.33 Billion | CN¥787.88 Million | ▲ +3.5 pp |
| 2016 | 59.8% | CN¥1.37 Billion | CN¥2.29 Billion | CN¥2.11 Billion | CN¥736.37 Million | ▲ +14.1 pp |
| 2015 | 45.6% | CN¥717.17 Million | CN¥1.57 Billion | CN¥1.43 Billion | CN¥717.73 Million | ▲ +1.2 pp |
| 2014 | 44.4% | CN¥633.99 Million | CN¥1.43 Billion | CN¥1.22 Billion | CN¥589.82 Million | ▼ -18.3 pp |
| 2013 | 62.7% | CN¥806.15 Million | CN¥1.29 Billion | CN¥1.14 Billion | CN¥334.13 Million | ▼ -12.5 pp |
| 2012 | 75.2% | CN¥846.39 Million | CN¥1.13 Billion | CN¥1.12 Billion | CN¥273.03 Million | ▼ -12.4 pp |
| 2011 | 87.6% | CN¥864.61 Million | CN¥987.45 Million | CN¥1.05 Billion | CN¥182.48 Million | ▲ +30.2 pp |
| 2010 | 57.3% | CN¥125.78 Million | CN¥219.39 Million | CN¥322.95 Million | CN¥197.17 Million | ▲ +3.3 pp |
| 2009 | 54.0% | CN¥86.01 Million | CN¥159.19 Million | CN¥192.51 Million | CN¥106.50 Million | ▲ +34.7 pp |
| 2008 | 19.4% | CN¥18.10 Million | CN¥93.43 Million | CN¥121.26 Million | CN¥103.16 Million | — |